Dry Powder Inhaler Global Market Report 2024

The dry powder inhaler market size has grown strongly in recent years. It will grow from $20.18 billion in 2023 to $21.25 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historical period can be attributed to factors such as renewed interest in sustainable building materials, cultural preservation and heritage restoration, the rise in green building practices, local sourcing, community involvement, and regulatory support including building codes.

The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $25.82 billion in 2028 at a compound annual growth rate (CAGR) of 5%. The anticipated growth in the forecast period can be attributed to continued emphasis on sustainability, global urbanization trends, advancements in manufacturing processes, government incentives and policies supporting sustainable construction, and global economic factors. Major trends expected in the forecast period include increased research and development in the construction industry, renewed interest in traditional building techniques, advancements in material technology, evolving architectural and design trends, and regulatory support for sustainable construction practices.

The anticipated increase in the prevalence of respiratory diseases is poised to drive the growth of the dry powder inhaler market in the future. Respiratory diseases encompass a wide range of medical conditions affecting the respiratory system, and dry powder inhalers play a crucial role in treating conditions such as asthma, COPD, and cystic fibrosis. These inhalers deliver medication directly to the lungs, offering a promising alternative to traditional drug delivery methods for respiratory diseases. For example, reports from the Australian Institute of Health and Welfare in June 2023 indicated a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021 in Australia. Thus, the growing prevalence of respiratory diseases is expected to propel the growth of the dry powder inhaler market.

The increasing levels of air pollution are also anticipated to contribute to the growth of the dry powder inhaler market. Air pollution, measured by the concentration of various pollutants in the atmosphere, leads to respiratory issues, making dry powder inhalers a preferred delivery method for medications that alleviate symptoms and manage respiratory conditions exacerbated by airborne pollutants. In 2022, the United States Environmental Protection Agency reported approximately 66 million tons of pollutants released into the atmosphere in the United States. Additionally, in March 2023, IQAir reported that Iraq was the second most polluted country with 80.1 µg/m3, 16 times higher than the WHO PM2.5 annual guideline in 2022. Therefore, the rising levels of air pollution are expected to drive the growth of the dry powder inhaler market.

The stringent regulatory guidelines are anticipated to pose challenges to the growth of the dry powder inhaler market. The imposition of rigorous testing and compliance requirements has increased the hurdles for product development, usage, and market entry. In September 2023, The Scottish Government released a consultation draft guidance on quality prescribing for respiratory illness, emphasizing the importance of effective use of dry powder inhalers (DPIs) and providing information on inhaler choice and technique. Strict regulatory guidelines may impede the growth of the dry powder inhaler market.

Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), and expanding their product portfolios. Muscarinic antagonists are drugs that inhibit the muscarinic acetylcholine receptor and are used to treat various illnesses, including COPD. For instance, Glenmark Pharmaceuticals Limited launched Tiogiva, a long-acting muscarinic antagonist dry powder inhaler (DPI) for COPD treatment in the UK in June 2021. The DPI functions by relaxing the muscles in the airways, facilitating breathing and requiring only once-a-day usage.

In February 2021, Catalent Inc. acquired Acorda Therapeutics Inc., expanding its capabilities in DPI manufacturing and adding a commercial-stage product to its portfolio, emphasizing the growing significance of DPI therapies for respiratory and neurological diseases. Acorda Therapeutics Inc. produces various DPIs for patients with respiratory diseases.

Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd., Beximco Pharmaceuticals Ltd., Sava Healthcare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals, Presspart Manufacturing Ltd., SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.

North America was the largest region in the dry powder inhaler market in 2023. The regions covered in the dry powder inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Dry Powder Inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A dry powder inhaler (DPI) is a medical device designed for delivering medication in the form of dry powder directly to the lungs. It is primarily used for treating respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). To effectively use a DPI, it is crucial for the user to inhale rapidly and deeply, allowing the medication to reach the lungs.

The main types of dry powder inhalers include single-dose inhalers and multi-dose inhalers. Single-dose inhalers are devices that administer medication directly to the lungs in the form of dry powder. These devices can be either manually operated or digitally operated, and they find applications in treating conditions such as asthma, COPD, cystic fibrosis, and others. Various end-users, including hospitals and clinics, homecare settings, and ambulatory surgical centers, utilize these inhalers.

The dry powder inhaler market research report is one of a series of new reports that provides dry powder inhaler market statistics, including dry powder inhaler industry global market size, regional shares, competitors with a dry powder inhaler market share, detailed dry powder inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the dry powder inhaler industry. This dry powder inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dry powder inhaler market consists of sales of dry powder forms, spiriva handihalers, breath-activated inhalers, rotahalers, diskus devices, and twisthaler inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.